Wang Xin-yan, Wang Hai-jiao, Li Xiu-qin
Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang, 110004, China.
Tumour Biol. 2013 Aug;34(4):2275-81. doi: 10.1007/s13277-013-0769-0. Epub 2013 Apr 6.
We investigated the association between peroxiredoxin III (PRX III) and chemotherapy resistance in ovarian cancer. Patient's specimens were taken at the time of surgery. Determination of resistance is based on whether first diagnosis of relapse occurred within 6 months after the cessation of chemotherapy. PRX III expression was immunohistochemically determined in paraffin-embedded specimens from platinum-resistant (Pt-resistant) and platinum-sensitive (Pt-sensitive) patients. The Pt-resistant group had significantly higher PRX III protein compared to the Pt-sensitive group. The two groups showed no significant differences in pathological classification and age, although they differed significantly in tissue differentiation and stage. PRX III protein was significantly higher in the Pt-resistant serous carcinomas, in moderately and poorly differentiated, and in stage III and IV ovarian cancer tissues compared to the Pt-sensitive group. PRX III may be associated with drug resistance in ovarian cancer.
我们研究了过氧化物酶III（PRX III）与卵巢癌化疗耐药性之间的关联。在手术时采集患者标本。耐药性的判定基于化疗停止后6个月内是否首次诊断为复发。通过免疫组织化学方法测定铂耐药（Pt耐药）和铂敏感（Pt敏感）患者石蜡包埋标本中的PRX III表达。与Pt敏感组相比，Pt耐药组的PRX III蛋白显著更高。两组在病理分类和年龄方面无显著差异，尽管在组织分化和分期方面差异显著。与Pt敏感组相比，PRX III蛋白在铂耐药的浆液性癌、中低分化以及III期和IV期卵巢癌组织中显著更高。PRX III可能与卵巢癌的耐药性有关。
